The interplay between thrombosis, stress, and social risk factors in trans persons on gender affirming hormone therapy.

Although the use of exogenous hormone therapy has been the primary focus of transgender and gender diverse (trans) health research, additional factors that contribute to thrombosis warrant further evaluation in this population. Because stress is a trigger of hypercoagulability, disparities in thrombosis experienced by trans persons should be examined through a minority stress lens. Given the high burden of socioeconomic disparities experienced by trans persons and the potential moderating effect of socioeconomic status on minority stress, clinicians and researchers should assess the role of social risk factors in exacerbating stress and thrombosis in this population. Clotting during mental stress is thought to have evolved, in part, as an adaptive response in anticipation of bleeding from injury, acting via 2 hormonal pathways: catecholamine- and glucocorticoid-mediated pathways. Because trans persons face significant socioeconomic disparities, the theorized role of social risk factors in exacerbating stress-induced hypercoagulability should be studied in this population. This is especially relevant for those on gender affirming hormone therapy, which can have compounding prothrombotic effects. We define sex via the genetic complement of chromosomes, including cellular and molecular differences, as well as physical traits such as genitalia and reproductive organs. We define gender as comprising the social, environmental, cultural, and behavioral factors that influence a person's self-identity, health, and well-being.